Recombinant MBL

Recombinant MBL (rMBL) is a recombinant protein therapeutic being developed by the CHA Vaccine Research Institute for the suppression of infectious diseases. Mannose-binding lectin (MBL) is a key pattern recognition molecule of the innate immune system that identifies and binds to specific carbohydrate patterns on the surfaces of various pathogens, including bacteria, viruses, and fungi. This binding triggers the activation of the lectin complement pathway, which facilitates pathogen opsonization, phagocytosis, and direct lysis, while also modulating inflammatory responses. rMBL is intended to supplement or enhance the host's natural defenses, particularly in cases of MBL deficiency or severe infection where the endogenous immune response is insufficient. The program is currently in the preclinical feasibility stage.

Other names

recombinant mannose-binding lectin